Skip to main content

Latest news

Free registration

Medicine Matters is developed for healthcare professionals as

a premier resource for the latest clinical information in medicine.

Global RA burden ‘significant, yet under-recognized’

Stethoscope and globe

Almost 20 million people worldwide were living with rheumatoid arthritis in 2017, with over a million new cases diagnosed each year, according to estimates from the Global Burden of Diseases, Injuries, and Risk Factors Study.

Preliminary trial results support further investigation of low-dose IL-2 therapy for SLE

Doctor and needle

The low-dose recombinant IL-2 therapy aldesleukin has a favorable safety profile and may restore regulatory T-cell homeostasis in people with systemic lupus erythematosus, suggest findings from a proof-of-concept phase I/IIa clinical trial.

Alcohol consumption linked to axSpA progression

Alcoholic drinks

Alcohol consumption may be a modifiable risk factor for spinal structural damage among patients with axial spondyloarthritis, researchers report.

Meta-analysis questions use of osteoporosis treatments to reduce mortality risk

Osteoporosis bone

Findings from a meta-analysis published in JAMA Internal Medicine indicate that drug treatments for osteoporosis, particularly bisphosphonates, are not associated with a significant reduction in overall mortality risk.

Support for switching between upadacitinib and adalimumab in RA patients

Rheumatoid arthritis medication

48-week results from the SELECT-COMPARE study indicate that upadacitinib has sustained efficacy in patients with rheumatoid arthritis, and that individuals with an inadequate response to upadacitinib or adalimumab may benefit from switching to the alternate therapy.

NSAIDs contribute ‘substantially’ to increased CVD risk in osteoarthritis

New Content Item

People with osteoarthritis have a significantly higher risk for developing cardiovascular disease than those without, and the use of nonsteroidal anti-inflammatory drugs mediates a considerable proportion of this association, researchers report.

Machine learning shows promise for predicting TNF inhibitor response

Machine learning

A machine-learning model may help to predict which rheumatoid arthritis patients are likely to respond to treatment with TNF inhibitors, researchers report.

FINCH 2: Further evidence for filgotinib as a treatment option for RA


Rheumatoid arthritis patients with an inadequate response or intolerance to biologic DMARDs who are treated with the selective JAK1 inhibitor filgotinib are more likely to achieve a clinical response than those given placebo, phase III trial results suggest.

Partial knee replacement recommended for medial compartment osteoarthritis

Knee arthroplasty concept image (symbolic image with model)

Partial knee replacement is more cost-effective than total knee replacement over 5 years for patients with late-stage isolated medial compartment osteoarthritis of the knee, show results of the TOPKAT trial published in The Lancet.

Latest headlines

19-09-2019 | Rheumatoid arthritis | News

IL-1 inhibition may benefit for people with RA, type 2 diabetes

Treatment with the interleukin-1 inhibitor anakinra improves both glycemic and inflammatory endpoints among patients with rheumatoid arthritis and type 2 diabetes, suggest findings from the TRACK trial.

18-09-2019 | Psoriatic arthritis | News

Ustekinumab efficacious in TNF-inhibitor naïve PsA patients

Ustekinumab elicits a greater clinical response versus placebo in patients with psoriatic arthritis naïve to tumor necrosis factor inhibitors, regardless of prior conventional synthetic DMARD or methotrexate exposure, PSUMMIT 1 and PSUMMIT 2 study data show.

17-09-2019 | Rheumatoid arthritis | Highlight | News

Global RA burden ‘significant, yet under-recognized’

Almost 20 million people worldwide were living with rheumatoid arthritis in 2017, with over a million new cases diagnosed each year, according to estimates from the Global Burden of Diseases, Injuries, and Risk Factors Study.

In depth

21-08-2019 | Tofacitinib | Feature | Article

Tofacitinib black box warning: A cause for concern?

Roy Fleischmann puts the new FDA boxed warning of increased pulmonary embolism and death risk with tofacitinib into context for rheumatologists and their patients.

23-07-2019 | Axial spondyloarthritis | Feature | Article

Into the clinic: Certolizumab pegol for nonradiographic axSpA

medwireNews talks to Walter Maksymowych and Marina Magrey about the impact of the recent FDA approval of certolizumab pegol for nonradiographic axial spondyloarthritis, and why the approval happened so much later in the USA than in Europe.

10-06-2019 | Psoriatic arthritis | Feature | Article

A closer look at guidelines for the management of PsA

Laura Coates talks to medwireNews about the latest ACR/NPF guidelines for managing psoriatic arthritis, discussing the evidence supporting the recommendations and how they compare with others.

Image Credits